| Print
Janux Therapeutics (JANX)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T CellEngagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with atumor antigen-binding domain and a costimulatory CD28 binding domain.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Janux Therapeutics Inc Third Quarter Earnings Results for 2026 | 2026-11-06T00:00:00 |
| Janux Therapeutics Inc Second Quarter Earnings Results for 2026 | 2026-08-07T00:00:00 |
| Janux Therapeutics Inc Annual General Meeting for 2026 | 2026-06-11T13:30:00 |
| Janux Therapeutics Inc First Quarter Earnings Results for 2026 | 2026-05-08T00:00:00 |
| Janux Therapeutics Inc Annual Report for 2025 | 2026-02-27T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Janux Therapeutics Inc Third Quarter Earnings Results for 2025 | 2025-11-06T00:00:00 |
| Janux Therapeutics Inc Second Quarter Earnings Results for 2025 | 2025-08-07T00:00:00 |
| virtual R&D Day | 2025-07-24T13:30:00 |
| Janux Therapeutics Inc Annual General Meeting for 2025 | 2025-06-11T13:30:00 |
| Janux Therapeutics Inc First Quarter Earnings Results for 2025 | 2025-05-08T00:00:00 |
| Janux Therapeutics Inc Annual Report for 2024 | 2025-02-27T00:00:00 |
| Janux Therapeutics Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies 2024 | 2024-12-02T16:30:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.